Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Progenta in pre-menopausal women with symptomatic leiomyomata
NCT01069094Phase 2Completed
- Sponsor
- Repros Therapeutics Inc.
- Start
- Jul 2004
- Primary completion
- Jan 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of telapristone in uterine leiomyoma (5 arms), sponsored by Repros Therapeutics Inc. Primary endpoint: Safety of Progenta at 90 days. Started Jul 2004; status: completed.
02
Drugs
telapristone
03
Conditions
uterine leiomyoma
Beyond the preview
Go deeper on NCT01069094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01069094.